Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
Chemical assay confirms high-grade uranium
How to Invest in Manganese Stocks
$14M Placement to Fund Acquisition & Exploration
Green Technology Metals
Laramide Identifies Targets for 15,000 Meter Drill Program...
Coinbase Expands USDC Rewards to Canada
NVIDIA Facing Weak Demand for New Chip as...
Newmont Withdraws from Mount Coolon Joint Venture, GBM...
LimeWire acquires Fyre Festival, asking ‘What Could Possibly...
Gold Market Dynamics Shifting as China-US Trade Tensions...
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Investing

5 Biggest Biotechnology ETFs in 2024

by admin November 14, 2024
November 14, 2024
5 Biggest Biotechnology ETFs in 2024

Investing in the biotech industry can be a long road to gains given the sector’s volatility.

Even with a good understanding of the system, no one can predict which treatment, device or therapy will give the biggest return, making biotech exchange-traded funds (ETFs) a more secure option than individual biotech stocks.

An ETF is a relatively safe investment route that can minimize losses while offering exposure to multiple companies instead of focusing on the gains and losses of a single biotech stock. With that in mind, here’s a brief look at the five top biotechnology ETFs by total assets under management (AUM). Data was sourced from ETFdb.com on November 13, 2024, and all data was current as of that time.

1. SPDR S&P Biotech ETF (ARCA:XBI)

Company Profile

Total AUM: US$7.82 billion

Established on February 6, 2006, the SPDR S&P Biotech ETF is a largely balanced fund in terms of weight that focuses mostly on biotech companies with some pharmaceutical companies. As noted by ETF.com, it focuses on small- and micro-cap companies, which makes the weight of each holding smaller than the holdings of other ETFs in this sector.

The SPDR S&P Biotech ETF has 144 companies in its portfolio, with the top three being Incyte (NASDAQ:INCY) at a weight of 3.11 percent, United Therapeutics (NASDAQ:UTHR) at a weight of 2.86 percent and Gilead Sciences (NASDAQ:GILD) at 2.7 percent.

2. iShares NASDAQ Biotechnology ETF (NASDAQ:IBB)

Company Profile

Total AUM: US$7.33 billion

The iShares NASDAQ Biotechnology ETF was launched on February 5, 2001, and tracks 211 holdings. This iShares ETF is a diversified fund in that it provides exposure to biotechnology, pharmaceutical and life science tools and services. Its overarching investment goal is to track NASDAQ-listed companies focused on these areas.

Its top three holdings are: Gilead Sciences at a weight of 9.35 percent, Vertex Pharmaceuticals (NASDAQ:VRTX) at 8.02 percent and Amgen (NASDAQ:AMGN) at 7.76 percent.

3. ARK Genomic Revolution Multi-Sector ETF (ARCA:ARKG)

Company Profile

Total AUM: US$1.31 billion

The ARK Genomic Revolution Multi-Sector ETF came into existence on October 31, 2014, and tracks 38 holdings. This ETF follows companies that develop products such as CRISPR technology, bioinformatics, molecular diagnostics and stem cells.

This top biotechnology ETF’s three most significant company holdings are: CRISPR Therapeutics (NASDAQ:CRSP) at a weight of 7.05 percent, Recursion Pharmaceuticals (NASDAQ:RXRX) at a weight of 6.91 percent and Twist Bioscience (NASDAQ:TWST) at 8.57 percent.

4. First Trust NYSE Arca Biotechnology Index (ARCA:FBT)

Company Profile

Total AUM: US$1.21 billion

The First Trust NYSE Arca Biotechnology ETF entered the market on June 23, 2006, and aims to track the NYSE Arca Biotechnology Index as closely as it can. Companies in this fund are generally involved in areas such as recombinant DNA technology, molecular biology, genetic engineering and genomics.

The fund has only 31 holdings; this means they are largely equally weighted. The top three holdings of the fund are the following companies: Exelixis (NASDAQ:EXEL) at a 4.31 percent weight, Intra-Cellular Therapies (NASDAQ:ITCI) at 3.83 percent and Incyte (NASDAQ:INCY) at 3.8 percent.

Natera (NASDAQ:NTRA) at a 4.78 percent weight, Bruker (NASDAQ:BRKR) representing a 4.09 percent weight, and Halozyme Therapeutics (NASDAQ:HALO), coming in at a 3.89 percent weight.

5. Direxion Daily S&P Biotech Bull 3x Shares ETF (ARCA:LABU)

Company Profile

Total AUM: US$956.65 billion

Founded on May 28, 2015, the Direxion Daily S&P Biotech Bull 3x Shares ETF does not mirror an index. Instead, its goal is to obtain daily investment results of at least 300 percent of the S&P Biotechnology Select Industry Index.

The Direxion Daily S&P Biotech Bull 3x Shares ETF has 142 holdings. The top stocks in this ETF by weight are Incyte with a 2.96 percent weight, United Therapeutics with a weight of 2.71 percent and Gilead Sciences at a weight of 2.7 percent.

Securities Disclosure: I, Lauren Kelly, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

previous post
Grande Portage Announces First Closing of Non-Brokered Private Placement — Pursuant to the Listed Issuer Financing Exemption
next post
NextSource Materials Closes Final Tranche of Private Placement for Additional Gross Proceeds of CAD$720,800

You may also like

Shell Contract Consolidates Top Tier Global Energy Position

September 11, 2025

What Does a Liberal Win Mean for Canada’s...

April 30, 2025

Market Pain, Strategic Gain: Pilbara Minerals’ Dale Henderson...

June 28, 2025

Stallion Uranium Completes First Tranche of Non-Brokered Private...

August 21, 2025

Asara Resources

July 8, 2025

Licence Application Granted for Ulytau Uranium Project

September 4, 2024

Carbonxt Completes Share Purchase Plan

April 8, 2025

Alvopetro Announces Q3 2024 Results and an Operational...

November 7, 2024

Group Eleven Announces Uplisting to OTCQB Market

May 24, 2025

Canadian Critical Minerals Receives Offer to Purchase Interest...

October 2, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Chemical assay confirms high-grade uranium

      September 17, 2025
    • How to Invest in Manganese Stocks

      September 17, 2025
    • $14M Placement to Fund Acquisition & Exploration

      September 17, 2025
    • Green Technology Metals

      September 17, 2025
    • Laramide Identifies Targets for 15,000 Meter Drill Program at Kazakhstan Uranium Project

      September 17, 2025
    Promotion Image

    banner ads

    Categories

    • Business (856)
    • Economy (829)
    • Investing (2,834)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved